Navigation Links
Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
Date:11/18/2010

alysis confirmed that PX-866 is rapidly metabolized to a more potent derivative. PX-866 Development Program Oncothyreon has initiated a Phase 1/2 trial of PX-866 in combination with docetaxel and plans to begin three additional Phase 1/2 and Phase 2 trials of PX-866 in multiple tumor types, either in combination with another targeted agent or as a single agent.

The ongoing Phase 1/2 combination trial includes a dose escalation of PX-866 in combination with docetaxel administered at the standard dose of 75 mg/m2 in patients with advanced cancer for which docetaxel is considered standard of care. Once the recommended dose of PX-866 in combination with docetaxel is established, the Phase 2 portion will consist of two independent arms examining PX-866 in combination with docetaxel in second or third line non-small cell lung cancer and in second or third line squamous cell carcinoma of the head and neck. About PX-866 PX-866 is an irreversible inhibitor of the PI-3-kinase/PTEN/AKT pathway, a critical cell signaling pathway that is activated in many types of human cancer. Aberrant activation and regulation of PI-3 kinase is implicated in a large proportion of human cancers, where it leads to increased proliferation and inhibition of apoptosis (programmed cell death). About Oncothyreon Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit href="http://www.oncothyreon.com/">www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward lookin
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Oncothyreon Reports Third Quarter 2010 Financial Results
2. Oncothyreon to Present at JMP Securities Healthcare Conference
3. ONCOTHYREON ANNOUNCES PRICING OF $14.9 MILLION PRIVATE PLACEMENT
4. ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER
5. Oncothyreon reports second quarter 2010 financial results
6. Oncothyreon announces second quarter 2010 financial results conference call
7. Oncothyreon announces presentations at upcoming investor conferences in June
8. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
9. Oncothyreon reports full year and fourth quarter 2009 financial results
10. Oncothyreon reports first quarter 2010 financial results
11. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 ... ones in the biotech start-up dense realm of Boston-Cambridge, ... alliances and able investors. James Sherley, the Director of ... made increasing the local and national visibility of his ... in September 2013. , In addition to a social ...
(Date:8/28/2014)... SPIE Fellow Glenn Boreman, Professor and ... and Director of the Center for Optoelectronics and Optical ... and co-founder and Chairman of the Board of Plasmonics, ... Vice President of SPIE, the international society for optics ... recent election results at the Annual General Meeting of ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2
(Date:8/29/2014)... how the repeated climatic shifts over the last ... genetic diversity, a team of researchers led by ... Carnaval developed a new biodiversity metric called "phylogeographic ... the genetic variation within species is restricted in ... of biology, and 14 other researchers from institutions ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
(Date:8/28/2014)... Invasives is now available from the Lady Bird Johnson ... for identifying harmful non-native plant, insect and other invasive ... States cause about $137 billion in economic and other ... kill native plants and more. , "By having streamlined ... invasive species occur, we,re more likely to catch these ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... get their first solid food before 4 months of age ... developing Type 1 diabetes, University of Colorado researchers have found. ... and the CU School of Medicine,s Barbara Davis Center for ... mother is still breast-feeding the baby when solid foods, particularly ...
... N.J. -- The New Jersey Commission on Spinal Cord Injury ... grants, which exceed $1.2 million, fund studies of assisted walking ... spinal cord injury (SCI) and the effects of electrical stimulation ... the ability to advance research to find new treatments that ...
... -- Christopher Field, the founding director of Carnegie,s Department ... Germany,s most prestigious prizes, the Max Planck Research Prize ... knowledge of how life on Earth responds to climate ... biosphere and the atmosphere their work also helps us ...
Cached Biology News:Infants' food linked to higher, lower Type 1 diabetes risk 2Kessler Foundation awarded more than $1.2 million in grants by the NJ Commission on Sci Research 2Kessler Foundation awarded more than $1.2 million in grants by the NJ Commission on Sci Research 3Carnegie's Chris Field receives Max Planck Research Prize 2
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
...
... biological cells for DNA isolation. ... plates (includes 96 well plate adapters ... across the entire plate length (max ... Can be used for soil, microorganisms, ...
... Chicken polyclonal to LYZL6 ( ... Antigen: Synthetic ... DYKSYSENLC HVDCQD , corresponding to amino ... Entrez Gene ID: ...
Biology Products: